Prostaglandin E2

Prostaglandin E2 (PGE2) is a bioactive lipid mediator belonging to the prostaglandin family of eicosanoids, biosynthesized from arachidonic acid through the sequential actions of phospholipase A2 and Cyclooxygenase 2 (COX-2). It is one of the most widely studied and pleiotropic of all prostanoid signaling molecules, playing central roles in the regulation of inflammation, pain sensitization, fever, immune modulation, and vascular tone. PGE2 exerts its effects by binding to four G-protein-coupled receptor subtypes (EP1–EP4), enabling context-dependent downstream signaling that can either promote or resolve inflammatory responses depending on tissue and cellular environment. Elevated PGE2 production is a hallmark of acute and chronic inflammatory states, and its measurement in biological fluids and tissues serves as a widely accepted biomarker of inflammatory activity.

Beyond classical inflammation, PGE2 occupies a critical role at the interface of immunity and oncology. Within the tumor microenvironment, PGE2 functions as a potent immunosuppressive mediator, dampening antitumor immune responses alongside factors such as vascular endothelial growth factor A (VEGFA) and Interleukin-6 (IL-6). Its involvement in oxidative stress signaling, including cross-talk with nuclear factor erythroid 2-related factor 2 (Nrf2) and nuclear factor kappa B (NF-κB) pathways, further positions it as a convergence point for inflammatory and redox regulation across multiple disease contexts. Therapeutic strategies targeting PGE2 biosynthesis — most prominently through COX-2 inhibition — remain among the most clinically deployed anti-inflammatory interventions in medicine.